5-HT5A antagonists reduced hyperactivity and improved cognition in Fmr1 KO rats, and thus might be used in Fragile X patients with concomitant attention deficit and hyperactivity disorder (ADHD). Here, HTR5A is linked to attention deficit-hyperactivity disorder.